A transgenic platform for testing drugs intended for reversal of cardiac remodeling identifies a novel 11βHSD1 inhibitor rescuing hypertrophy independently of re-vascularization.
<h4>Rationale</h4>Rescuing adverse myocardial remodeling is an unmet clinical goal and, correspondingly, pharmacological means for its intended reversal are urgently needed.<h4>Objectives</h4>To harness a newly-developed experimental model recapitulating progressive heart fai...
Saved in:
Main Authors: | Oren Gordon, Zhiheng He, Dan Gilon, Sabine Gruener, Sherrie Pietranico-Cole, Amit Oppenheim, Eli Keshet |
---|---|
Format: | article |
Language: | EN |
Published: |
Public Library of Science (PLoS)
2014
|
Subjects: | |
Online Access: | https://doaj.org/article/77a08bea49c04c21b9e31289f1f76e3e |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Adipocyte hypertrophy and lipid dynamics underlie mammary gland remodeling after lactation
by: Rachel K. Zwick, et al.
Published: (2018) -
Irisin is a pro-myogenic factor that induces skeletal muscle hypertrophy and rescues denervation-induced atrophy
by: Musarrat Maisha Reza, et al.
Published: (2017) -
Intended outcome expands in time
by: Mukesh Makwana, et al.
Published: (2017) -
The Mycobacterial DNA Methyltransferase HsdM Decreases Intrinsic Isoniazid Susceptibility
by: Xinling Hu, et al.
Published: (2021) -
Serum Zinc and Selenium Concentrations in Patients with Hypertrophy and Remodelling of the Left Ventricle Secondary to Arterial Hypertension
by: Paweł Gać, et al.
Published: (2021)